On the stock market since 2021, it operates in the world of health and science. It has 140 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 19% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades 57% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 10% a year on average.
Sales run at $34.9M a year. A small number, but proof the product has real buyers.
A loss of $746K against $34.9M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.10. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 2 years. After that, the company needs to find new money.
On our five-subject report card, SYDRF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SYDRF is a high-risk stock — not yet profitable, and its future rides on its product catching on.